MT-7117 is an investigational drug.
There have been 12 clinical trials for MT-7117.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 11th 2023.
The most common disease conditions in clinical trials are Protoporphyria, Erythropoietic, Sclerosis, and Scleroderma, Systemic. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Pharma Corporation, and Mitsubishi Tanabe Pharma America Inc.